A gene signature related to memory B cells (111) was reported to be associated with clinical benefit and improved survival in anti-PD-1- and anti-CTLA-4-treated melanoma patients and in anti-PD-L1-treated urothelial carcinoma (112). Here, CTLA4 is linked to melanoma.